冠心病患者支架置入术前后外周血Lp(a)、hs-CRP及IL-6水平变化的临床意义被引量：1

Clinical Significance of Variety of Lp(a),hs-CRP and IL-6 Level before and after Percutaneous Coronary Intervention in Patients with Coronary Heart Disease

下载PDF

导出

摘要目的:探讨冠心病患者支架置入术前后Lp(a)、Hs-CRP和IL-6水平变化。方法:121例行冠状动脉内支架置入术的冠心病患者,分别在术前、术后24小时检测患者外周血Lp(a)、Hs-CRP和IL-6水平,并选择冠脉造影结果阴性的45例非冠心病者(对照组)进行比较,测定Lp(a)的浓度、Hs-CRP和IL-6水平。结果:术前患者外周血Lp(a)、Hs-CRP和IL-6水平明显高于对照组(P<0.01)。术后患者外周血Lp(a)、Hs-CRP和IL-6水平明显低于术前(P<0.05)。结论:外周血Lp(a)、Hs-CRP和IL-6水平与冠心病密切相关,可为冠心病患者冠状动脉支架置入术后的早期炎定反应的评估指标。 Objective：To investigate the variety and clinical significance of Lp（a）,hs-CRP and IL-6 before and after percutaneous coronary intervention（PCI） in patients with coronary heart disease（CHD） Methods：121 CHD patients who have taken PCI and 45 people whose coronarography are normal were enrolled in the study.The serum level of Lp（a）,hs-CRP and IL-6 were tested befor and 24 hours after PCI.Results：Lp（a）,hs-CRP and IL-6 level of patients before PCI were significantly higher than that of normal people（P0.01 ）,and were significantly higher than that before PCI（P0.05）.Conclusion：Lp（a）,hs-CRP and IL-6 levels are sensitive indicators that reflecting the early inflammation after PCI.

作者王秋波

机构地区吉林省四平市中心医院心内科

出处《中国医药导刊》 2011年第11期1857-1858,共2页 Chinese Journal of Medicinal Guide

关键词冠心病支架置入脂蛋白A 超敏C反应蛋白白介素-6 Coronary heart disease Percutaneous coronary inte rvention Lp（a） hs-CRP IL-6

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1刘明伟,蒋立虹.冠心病与心血管炎症标志物的研究进展[J].中华全科医学,2009,7(6):649-651. 被引量：15
2尚小明,赵宝春,戴秀华.不同类型炎症在冠心病发病中的意义——C-反应蛋白水平与基因型分析[J].国外医学（内科学分册）,2005,32(6):269-273. 被引量：11
3M. Bihari-Varga,G. Kostner,A. Czinner.LP(A) and the risk of coronary heart disease[J]. European Journal of Epidemiology . 1992 (1)
4Eckardstein AV,Schulte H,Cullen P,et al.Lp (a) further increases the risk of coronary events in men with high global cardiovascular risk. Journalism Assn of Community College . 2011
5Kronenberg F,Kronenberg MF,Kiechl S,et al.Roleof Lp (a) and APO (a) phenotype in ather ogenesis.Prospective results from the Bruneck study. Circulation . 1999
6Rath M,Niendorf A,Reblin T,et al.Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary by pass patients. Arteriosclerosis . 1989
7Horie H,TakahashiM,IzumiM,et al.Association ofan acure reduction in Lp(a)with coronary arteryrestenosis after percutaneous tvansluninal coronaryangiop lasly. Circulation . 1997

二级参考文献27

1王少波,周善存,陈以初.他汀类药物对冠心病患者C反应蛋白和胰岛素抵抗的影响[J].实用全科医学,2007,5(8):680-681. 被引量：8
2Oldgren J, James SK, Siegbahn A, et al. Lipoprotein-associated phospholipase A2 does not predict mortalily or its new ischaemic events in acute coronary syndrome patients[ J]. Eur Heart,2007,28 (5) :699- 704.
3Blankenberg S, Rupprecht HJ,Poirier O,et al. Plasma concentration and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease [ J ]. Circulation, 2003, 107 (10) : 1579-1585.
4Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes [ J ]. JAMA, 2002,106 ( 7 ) : 2894- 2900.
5Robertson L, Grip L, Mattsson HL, et al. Release of protein as well as activity of MMP-9 from unstable avterioscler plaques during percutaneous coronary intervention [J].J Intern Med, 2007,26 ( 2 ) : 659- 667.
6Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risks of coronary atery disease[ J]. JAMA,2001,28 (6) :2136-2142.
7Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial in- faraction at two years in patients presenting with acute coronary syndrome[ J]. Am J Cardiol,2007,99(10) :1364-1368.
8Mocatta T, Pilbrow AP, Cameron VA, et al. Plasma concentration of myeloperoxidase predict mortality after myocardial infaraction [ J ]. J Am Coil Cardiol,2007,49(7 ) : 1993-2000.
9Guray U, Erbay AR, Gury Y, et al. Levels of souble adhesion molecular in various clinical presentationation of coronary atherosclerosis [J]. Int J Cardio1,2004,96(2) :235-240.
10Tenger C, Sundborger A, Jawien J, et al. IL-18 accelerate atherosclerosis accompanied by elevation of IFN-gamma and CXCL 16 expression independently of T cells [ J ]. Arterioscler Thromb Vasc Biol, 2005,117(5) :791-796.